Targeted delivery of Fc-fused PD-L1 for effective management of acute and chronic colitis

Area of Science:

• Immunology
• Nanotechnology
• Gastroenterology

Background:

• The programmed cell death protein 1 (PD-1)/PD-1 ligand 1 (PD-L1) pathway is crucial in mucosal immunity and a potential target for inflammatory bowel disease (IBD).
• Systemic administration of PD-L1 can lead to unpredictable adverse effects due to generalized immunosuppression.

Purpose of the Study:

• To develop and evaluate ROS-responsive nanoparticles for targeted delivery of PD-L1-Fc to inflammatory sites in IBD.
• To assess the enhanced efficacy and safety profile of nanoparticle-formulated PD-L1-Fc compared to systemic administration in a mouse colitis model.

Main Methods:

• Development of reactive oxygen species (ROS)-responsive nanoparticles encapsulating PD-L1 fused to Fc (PD-L1-Fc).
• Administration of nanotherapeutics to a mouse model of colitis.
• Evaluation of inflammatory markers, immune cell infiltration, cytokine profiles, Treg/Th1/Tfh cell frequencies, gut microbiota composition, and short-chain fatty acid production.

Main Results:

• Nanoparticle-formulated PD-L1-Fc demonstrated superior efficacy in alleviating inflammatory symptoms compared to systemic PD-L1-Fc.
• The nanotherapeutic approach significantly mitigated the adverse effects associated with systemic PD-L1-Fc administration.
• PD-L1-Fc-loaded nanoparticles modulated cytokine production, reduced inflammatory cell infiltration, increased beneficial immune cell populations (Treg, Th1, Tfh), and positively altered gut microbiota and short-chain fatty acid levels.

Conclusions:

• ROS-responsive nanoparticles offer a promising strategy for targeted delivery of PD-L1-Fc in IBD treatment.
• This nanomedicine approach enhances therapeutic efficacy while improving the safety profile by minimizing systemic immunosuppression.
• PD-L1-Fc-decorated nanoparticles represent a novel and safe therapeutic option for managing inflammatory bowel disease.